1. Home
  2. VOR vs DRUG Comparison

VOR vs DRUG Comparison

Compare VOR & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

HOLD

Current Price

$13.73

Market Cap

767.4M

Sector

Health Care

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$89.10

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOR
DRUG
Founded
2015
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
767.4M
707.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
VOR
DRUG
Price
$13.73
$89.10
Analyst Decision
Buy
Strong Buy
Analyst Count
10
6
Target Price
$45.33
$129.25
AVG Volume (30 Days)
1.3M
152.2K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$23.18
52 Week High
$49.95
$123.75

Technical Indicators

Market Signals
Indicator
VOR
DRUG
Relative Strength Index (RSI) 42.32 61.55
Support Level $11.38 $69.83
Resistance Level $16.87 $91.69
Average True Range (ATR) 1.23 4.40
MACD -0.25 0.62
Stochastic Oscillator 3.32 84.50

Price Performance

Historical Comparison
VOR
DRUG

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: